CL2009000780A1 - Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k. - Google Patents
Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k.Info
- Publication number
- CL2009000780A1 CL2009000780A1 CL2009000780A CL2009000780A CL2009000780A1 CL 2009000780 A1 CL2009000780 A1 CL 2009000780A1 CL 2009000780 A CL2009000780 A CL 2009000780A CL 2009000780 A CL2009000780 A CL 2009000780A CL 2009000780 A1 CL2009000780 A1 CL 2009000780A1
- Authority
- CL
- Chile
- Prior art keywords
- heterocyclyl
- substituted
- composition
- pharmaceutical composition
- cancer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 abstract 1
- 102000038030 PI3Ks Human genes 0.000 abstract 1
- 108091007960 PI3Ks Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 150000005119 benzoxepines Chemical class 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4082708P | 2008-03-31 | 2008-03-31 | |
| US10222008P | 2008-10-02 | 2008-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2009000780A1 true CL2009000780A1 (es) | 2010-01-15 |
Family
ID=40790991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2009000780A CL2009000780A1 (es) | 2008-03-31 | 2009-03-30 | Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k. |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US7928248B2 (enExample) |
| EP (1) | EP2276767B1 (enExample) |
| JP (1) | JP5511786B2 (enExample) |
| KR (1) | KR101626996B1 (enExample) |
| CN (1) | CN102333779B (enExample) |
| AR (1) | AR071112A1 (enExample) |
| AU (1) | AU2009231885B2 (enExample) |
| BR (1) | BRPI0910346A2 (enExample) |
| CA (1) | CA2719032C (enExample) |
| CL (1) | CL2009000780A1 (enExample) |
| DK (1) | DK2276767T3 (enExample) |
| ES (1) | ES2480994T3 (enExample) |
| IL (1) | IL208359A (enExample) |
| MX (1) | MX2010010659A (enExample) |
| PE (1) | PE20091720A1 (enExample) |
| PL (1) | PL2276767T3 (enExample) |
| RU (1) | RU2506267C2 (enExample) |
| SI (1) | SI2276767T1 (enExample) |
| TW (1) | TWI443102B (enExample) |
| WO (1) | WO2009123971A1 (enExample) |
| ZA (1) | ZA201007218B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2250160B1 (en) | 2008-01-25 | 2015-11-11 | Millennium Pharmaceuticals, Inc. | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| WO2009123971A1 (en) | 2008-03-31 | 2009-10-08 | Genentech, Inc. | Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2010090716A1 (en) | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
| US20100233733A1 (en) * | 2009-02-10 | 2010-09-16 | Nodality, Inc., A Delaware Corporation | Multiple mechanisms for modulation of the pi3 kinase pathway |
| EA201200087A1 (ru) * | 2009-07-02 | 2012-07-30 | Новартис Аг | 2-карбоксамиды циклоаминомочевин, которые являются ингибиторами pi3k |
| RU2600927C2 (ru) | 2009-09-28 | 2016-10-27 | Ф.Хоффманн-Ля Рош Аг | Бензоксазепиновые ингибиторы pi3k и способы применения |
| PE20140918A1 (es) * | 2009-09-28 | 2014-08-06 | Hoffmann La Roche | Compuestos de benzoxepina inhibidores de la pi3k |
| WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
| EP2493866A1 (en) * | 2009-10-29 | 2012-09-05 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
| PT2496567T (pt) | 2009-11-05 | 2017-11-15 | Rhizen Pharmaceuticals S A | Novos moduladores de quinase benzopiran |
| US9073940B2 (en) | 2009-11-13 | 2015-07-07 | Merck Serono Sa | Tricyclic pyrazol amine derivatives |
| WO2011063126A1 (en) * | 2009-11-18 | 2011-05-26 | Satoshi Ohtake | Highly dispersible powders, compositions and methods for preparation |
| US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2012021615A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| UY33554A (es) | 2010-08-11 | 2012-02-29 | Millennium Pharm Inc | Heteroarilos y usos de los mismos |
| BR112013009166A2 (pt) * | 2010-10-13 | 2016-07-26 | Millennium Pharm Inc | heteroarilas e uso das mesmas. |
| RU2013143747A (ru) * | 2011-03-21 | 2015-04-27 | Ф. Хоффманн-Ля Рош Аг | Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения |
| KR101992311B1 (ko) | 2011-05-04 | 2019-09-27 | 리젠 파마슈티컬스 소시에떼 아노님 | 단백질 키나아제의 조절제로서 신규한 화합물 |
| EP2714675B1 (en) | 2011-05-27 | 2019-01-02 | Lexicon Pharmaceuticals, Inc. | 4h-thieno[3,2-c]chromene-based inhibitors of notum pectinacetylesterase and methods of their use |
| BR112014019209A2 (pt) | 2012-02-17 | 2017-07-04 | Hoffmann La Roche | compostos tricíclicos e métodos de uso para os mesmos |
| US8940742B2 (en) * | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| BR112014028881A2 (pt) | 2012-05-23 | 2017-06-27 | Hoffmann La Roche | populações de células, banco de células, métodos de obtenção de uma população de células, métodos de identificação de um fator, métodos de seleção, métodos de fornecimento de terapia, populações de hepatócitos e método de obtenção de células |
| KR101988079B1 (ko) | 2012-07-04 | 2019-06-11 | 리젠 파마슈티컬스 소시에떼 아노님 | 선택적 pi3k 델타 억제제 |
| WO2014068070A1 (en) | 2012-10-31 | 2014-05-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
| WO2014140073A1 (en) | 2013-03-13 | 2014-09-18 | F. Hoffmann-La Roche Ag | Process for making benzoxazepin compounds |
| KR20150130451A (ko) | 2013-03-15 | 2015-11-23 | 제넨테크, 인크. | 암 치료 방법 및 항암제 내성 예방을 위한 방법 |
| AU2014251038A1 (en) | 2013-04-08 | 2015-11-26 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| SG10201902074UA (en) | 2013-10-04 | 2019-04-29 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN113616656B (zh) | 2014-03-19 | 2023-02-17 | 无限药品股份有限公司 | 用于治疗PI3K-γ介导的障碍的杂环化合物 |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| JP6454419B2 (ja) | 2014-12-11 | 2019-01-16 | ナトコ ファーマ リミテッド | 抗癌剤としての７−（モルホリニル）−２−（Ｎ−ピペラジニル）メチルチエノ［２，３−ｃ］ピリジン誘導体 |
| ES2911886T3 (es) * | 2015-03-30 | 2022-05-23 | Jubilant Biosys Ltd | Derivados condensados tricíclicos de 1-(ciclo)alquilpiridin-2-ona útiles para el tratamiento del cáncer |
| AU2016322552B2 (en) | 2015-09-14 | 2021-03-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| PE20190403A1 (es) | 2016-07-29 | 2019-03-13 | Janssen Pharmaceutica Nv | Metodos para tratar el cancer de prostata |
| JP7029445B2 (ja) | 2016-09-02 | 2022-03-03 | ブリストル－マイヤーズ スクイブ カンパニー | 置換された三環式ヘテロ環化合物 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| WO2019018584A1 (en) | 2017-07-18 | 2019-01-24 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| JP2020527593A (ja) | 2017-07-18 | 2020-09-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | １，８−ナフチリジノン化合物およびその使用 |
| US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
| WO2019032632A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | ALKYLPHENYL COMPOUNDS |
| CN107805255B (zh) * | 2017-09-22 | 2020-06-16 | 中国药科大学 | 呋喃[3，2-b]吡啶-2(1H)-酮类化合物、制备方法和医药用途 |
| US20210017174A1 (en) | 2018-03-07 | 2021-01-21 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitor |
| CN110467629B (zh) * | 2018-05-09 | 2022-04-08 | 上海迪诺医药科技有限公司 | 苯醌衍生物、其药物组合物及应用 |
| MX2021008650A (es) | 2019-01-18 | 2021-11-03 | Nuvation Bio Inc | Compuestos heterociclicos como antagonistas de adenosina. |
| CN113939291A (zh) | 2019-01-18 | 2022-01-14 | 诺维逊生物股份有限公司 | 1,8-萘啶酮化合物及其用途 |
| CN114156414B (zh) * | 2021-11-30 | 2024-05-31 | 合肥工业大学 | 一种高效稳定CsPbI3无机钙钛矿电池的制备方法 |
| CN117209457B (zh) * | 2022-06-09 | 2025-08-15 | 四川师范大学 | 一种α-手性脒化合物的合成 |
| CN115403591A (zh) * | 2022-10-08 | 2022-11-29 | 河南师范大学 | 一种合成萘并噻吩并奥塞平并异喹啉酮类化合物的方法 |
| WO2025082467A1 (zh) * | 2023-10-19 | 2025-04-24 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8504702D0 (en) | 1985-02-23 | 1985-03-27 | Zyma Sa | Tricyclic compounds |
| FR2677356B1 (fr) | 1991-06-05 | 1995-03-17 | Sanofi Sa | Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant. |
| KR0126300B1 (ko) | 1992-12-28 | 1997-12-26 | 나이토 하루오 | 레티노이드 수용체(rar)에 결합하는 헤테로고리 탄산유도체 |
| AU1272597A (en) | 1995-11-17 | 1997-06-11 | E.I. Du Pont De Nemours And Company | Tricyclic herbicidal heterocycles |
| DE19831878C2 (de) * | 1998-07-17 | 2001-05-17 | Aventis Pharma Gmbh | Polycyclische Thiazolidin-2-yliden Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE19908533A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen |
| DE19908537A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
| DE19908538A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen |
| DE19908535A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
| US7273880B2 (en) | 1999-06-30 | 2007-09-25 | H. Lunbeck A/S | Selective NPY (Y5) antagonists |
| AU2001246494A1 (en) | 2000-03-03 | 2001-09-12 | Novartis Ag | Condensed thiazolamines and their use as neuropeptide y5 antagonists |
| US20040198791A1 (en) * | 2001-06-05 | 2004-10-07 | Yoshinari Sato | Fused imidazole derivative |
| US20040082602A1 (en) | 2002-07-19 | 2004-04-29 | Hagen Timothy J. | Substituted thiophene carboxamide compounds for the treatment of inflammation |
| MXPA05008400A (es) | 2003-02-07 | 2005-10-05 | Warner Lambert Co | Derivados de oxazolidinona n-sustituidos por un anillo triciclico, para su uso como agentes antibacterianos. |
| US20060106013A1 (en) | 2004-10-07 | 2006-05-18 | Boehringer Ingelheim International Gmbh | PI3-kinases |
| CN101039667A (zh) * | 2004-10-15 | 2007-09-19 | 辉瑞大药厂 | 双相性精神障碍和相关症状的治疗 |
| RU2281947C1 (ru) * | 2005-07-05 | 2006-08-20 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Аннелированные карбамоилазагетероциклы, фокусированная библиотека, фармацевтическая композиция и способ получения |
| AU2007281911B2 (en) * | 2006-08-04 | 2014-02-06 | Beth Israel Deaconess Medical Center | Inhibitors of pyruvate kinase and methods of treating disease |
| US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| WO2009123971A1 (en) | 2008-03-31 | 2009-10-08 | Genentech, Inc. | Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use |
-
2009
- 2009-03-30 WO PCT/US2009/038795 patent/WO2009123971A1/en not_active Ceased
- 2009-03-30 TW TW098110447A patent/TWI443102B/zh not_active IP Right Cessation
- 2009-03-30 MX MX2010010659A patent/MX2010010659A/es active IP Right Grant
- 2009-03-30 CL CL2009000780A patent/CL2009000780A1/es unknown
- 2009-03-30 CN CN200980120112.8A patent/CN102333779B/zh active Active
- 2009-03-30 KR KR1020107024488A patent/KR101626996B1/ko not_active Expired - Fee Related
- 2009-03-30 EP EP09726963.3A patent/EP2276767B1/en active Active
- 2009-03-30 SI SI200930981T patent/SI2276767T1/sl unknown
- 2009-03-30 DK DK09726963.3T patent/DK2276767T3/da active
- 2009-03-30 BR BRPI0910346A patent/BRPI0910346A2/pt not_active IP Right Cessation
- 2009-03-30 PL PL09726963T patent/PL2276767T3/pl unknown
- 2009-03-30 US US12/414,403 patent/US7928248B2/en active Active
- 2009-03-30 AR ARP090101126A patent/AR071112A1/es not_active Application Discontinuation
- 2009-03-30 AU AU2009231885A patent/AU2009231885B2/en not_active Ceased
- 2009-03-30 PE PE2009000466A patent/PE20091720A1/es not_active Application Discontinuation
- 2009-03-30 ES ES09726963.3T patent/ES2480994T3/es active Active
- 2009-03-30 CA CA2719032A patent/CA2719032C/en not_active Expired - Fee Related
- 2009-03-30 JP JP2011503076A patent/JP5511786B2/ja active Active
- 2009-03-30 RU RU2010143319/04A patent/RU2506267C2/ru not_active IP Right Cessation
-
2010
- 2010-10-03 IL IL208359A patent/IL208359A/en not_active IP Right Cessation
- 2010-10-08 ZA ZA2010/07218A patent/ZA201007218B/en unknown
-
2011
- 2011-01-31 US US13/018,068 patent/US8399690B2/en active Active
-
2013
- 2013-01-10 US US13/738,846 patent/US8846762B2/en active Active
-
2014
- 2014-07-29 US US14/446,154 patent/US9309265B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2009000780A1 (es) | Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k. | |
| CL2020003131A1 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
| CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| AR066214A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas | |
| CL2009000241A1 (es) | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. | |
| ECSP109934A (es) | Compuesto - 946 | |
| ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| UY33480A (es) | Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento. | |
| UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| DOP2014000008A (es) | 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk | |
| DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
| CL2011000504A1 (es) | Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer. | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
| NI201000145A (es) | DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET. | |
| MX2009001660A (es) | Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis. | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| CL2022001337A1 (es) | Derivados de piridopirimidinona como antagonistas de ahr | |
| UY32055A (es) | Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones. | |
| UY33806A (es) | ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7? | |
| CL2025001386A1 (es) | Compuestos derivados de hexahidropirano[3',4':4,5]pirrolo[2,3-d]pirimidina y uso para tratar cáncer. |